United Biomedical   Report issue

For profit Phase 1 Phase 2
Founded: Hauppauge NY United States (1983)
Status: Left NME R&D (2018)

Organization Overview

First Clinical Trial
1999
NCT00002353
First Marketed Drug
2013
terbutaline (bricanyl)
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

UBI Asia in Taiwan | UNITED BIOMEDCL | United Biomedical | United Biomedical Inc., Asia

Active Ingredients

Marketed Drugs (1)

terbutaline (bricanyl) (2013)

Drugs in Phase 2 Trials (2)

ub-421 (2 trials)

ub-612 (4 trials)

Drugs in Phase 1 Trials (4)

hiv-1 peptide vaccine, microparticulate monovalent (2 trials)

p3c541b (1 trial)

rgp120/hiv-1mn (1 trial)

ub-311 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Alzheimer Disease (Phase 1)

HIV Infections (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 10
  • # of Trial APIs: 6